Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best strong buy stocks to invest in according to Wall Street. In a report released on September 17, Christopher Raymond from Raymond James maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and set a price target of $85.00. BioMarin Pharmaceutical Inc. (BMRN): Among Small-Cap Healthcare Stocks Hedge Funds is Buying BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported total revenues of $825 million in fiscal Q2 2025, up 16% year-ov ...